Clinical trials: Human Immunodeficiency Virus Type 1
HIV Infection
Depot Contraception With and Without Lopinavir/Ritonavir
DMPA (depot medroxyprogesterone acetate or the 'depot' injection) is a widely used contraception. It is popular in woman with HIV as it probably still works when you take HIV drugs.
- Trial name
- NCT01231451
- Testing
- DMPA
- Where
- United Kingdom
- Volunteers
- 10 people
- Sponsor
- St Stephens Aids Trust
HIV Infections, Pregnancy
Active Immunization of HIV-1 Infected, Pregnant Women With CD4 Lymphocyte Counts >= 400/mm3: A Phase I Study of Safety and Immunogenicity of VaxSyn Recombinant gp160 (NOTE: Some Patients Receive Placebo)
To evaluate the safety of gp160 vaccine (VaxSyn) in HIV-1 infected pregnant women with CD4 counts >= 400 cells/mm3. To evaluate the immunogenicity of this vaccine in pregnant women and the passive acquisition of vaccine-specific…
- Conditions
- HIV Infections, Pregnancy, HIV Seronegativity
- Trial name
- NCT00000777
- Testing
- gp160 Vaccine (MicroGeneSys)
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
TMC114-C226: An Early Access Program to Evaluate the Long-term Safety and Tolerability of TMC114 Combined With a Low Dose of Ritonavir (TMC114/r) With Other Antiretrovirals, for HIV-1 Infected Patients Who Have Failed Multiple Antiretroviral Regimens.
The purpose of this study is to provide early access to TMC114 (a protease inhibitor) for HIV-1 infected patients with limited or no treatment options, who have failed multiple antiretroviral (ARV) regimens, and to evaluate the…
- Trial name
- NCT00245739
- Testing
- TMC-114
- Where
- 394 sites in United States, Belgium and 20 more
- Sponsor
- Tibotec Pharmaceuticals, Ireland
HIV Infections, HIV Seronegativity
Effectiveness of AIDSVAX B/E Vaccine in Intravenous Drug Users in Bangkok, Thailand
The purpose of this study is to determine if the vaccine, AIDSVAX B/E, will protect intravenous drug users from becoming infected with HIV.
- Trial name
- NCT00006327
- Testing
- MN rgp120/HIV-1 and A244 rgp120/HIV-1
- Where
- Thailand
- Volunteers
- 2,500 people, healthy volunteers welcome
- Sponsor
- VaxGen
HIV Infections
Extended Follow-Up of Participants in Preventive HIV Vaccine Studies in Uganda
Two previous studies of an HIV preventive vaccine, the STEP study and the Phambili study, were halted because people who received the vaccine were more likely to become infected with HIV.
- Trial name
- NCT01109342
- Where
- Uganda
- Volunteers
- healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV-1-infection
PRO 140 in Treatment-Experienced HIV-1 Subjects
The primary objectives of the trial are to assess the efficacy, clinical safety and tolerability parameters of PRO 140 in combination with failing ART (antiretroviral therapy) during the initial one-week treatment period, and in…
- Trial name
- NCT03902522
- Testing
- PRO 140
- Where
- 17 sites in United States
- Volunteers
- 6 people
- Sponsor
- CytoDyn, Inc.
HIV-1 Virologic Response
HIV Treatment Retention Interventions for Women Living With HIV (Siyaphambili Study)
The Siyaphambili Study is a sequential multistage adaptive randomized trial (SMART) to compare the effectiveness and durability of two behavioral interventions on the HIV-1 virologic response among female sex workers (FSW) living…
- Trial name
- NCT03500172
- Testing
- DTP, ICM
- Where
- South Africa
- Volunteers
- 1,391 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
HIV-1, HIV Infections
Phase 3 Open-Label Study to Evaluate Switching From Optimized Stable Antiretroviral Regimens Containing Darunavir to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) Plus Darunavir (DRV) in Treatment Experienced HIV-1 Positive Adults
The primary objective of this study is to evaluate the efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) fixed dose combination (FDC) plus darunavir (DRV) relative to current antiretroviral…
- Conditions
- HIV-1, HIV Infections, Acquired Immunodeficiency Syndrome
- Trial name
- NCT01968551
- Testing
- E/C/F/TAF, DRV, Baseline DRV- containing ARV regimen
- Where
- 62 sites in United States, Canada
- Volunteers
- 158 people
- Sponsor
- Gilead Sciences
HIV Infections
Intermittent Therapy in HIV-1 Infected Patients With Successful Viral Suppression Under Highly Active Antiretroviral Therapy (HAART)
Although lifelong continuous therapy with HAART remains the standard of care of HIV infection, allowing to achieve undetectable plasma viral RNA, restore CD4 cell count and provide substantial decline in HIV-related morbidity and…
- Trial name
- NCT00122551
- Testing
- Intermittent antiretroviral therapy
- Where
- 2 sites in France
- Volunteers
- 400 people
- Sponsor
- French National Agency for Research on AIDS and Viral Hepatitis
Impaired Cognition, Depression/Anxiety
Switching From Efavirenz/Atripla to Rilpivirine Among Patients With Neurocognitive or Neuropsychological Side Effects
Despite long-term use in clinical practice, chronic treatment with efavirenz (EFV) has been associated with persistent central nervous system symptoms or mild or even asymptomatic neurocognitive impairment.
- Conditions
- Impaired Cognition, Depression/Anxiety, Poor Quality Sleep, Quality of Life
- Trial name
- SWEAR (NCT02042001)
- Testing
- Immediate switch to TDF/FTC/RPV, Switch to TDF/FTC/RPV after 24 weeks
- Where
- 5 sites in Italy
- Volunteers
- 74 people
- Sponsor
- Azienda Ospedaliera San Gerardo di Monza
HIV Infections
Effect of Intermittent Aldesleukin Treatment With or Without Anti-HIV Drugs in HIV Infected People
The purpose of this study is to determine the effect of short cycles of recombinant interleukin-2 (also known as rIL-2 or aldesleukin) given with or without anti-HIV drugs in HIV infected patients.
- Trial name
- STALWART (NCT00110812)
- Testing
- IL-2
- Where
- 36 sites in United States, Argentina and 9 more
- Volunteers
- 267 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections, Vitamin A Deficiency
Vitamin A to Reduce HIV in Vaginal Secretions and Prevent Viral Transmission
HIV infected individuals with vitamin A deficiency may be more likely to transmit the virus to others than HIV infected individuals who have normal levels of vitamin A.
- Conditions
- HIV Infections, Vitamin A Deficiency, HIV Seronegativity
- Trial name
- NCT00053612
- Testing
- Vitamin A
- Volunteers
- 400 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Characterization of Acute and Recent HIV-1 Infections in Zurich.
Aim of the study: To study and to describe factors which could influence the course of primary HIV infection (PHI) and factors that in turn could be influenced through PHI.
- Trial name
- ZPHI (NCT00537966)
- Where
- Switzerland
- Volunteers
- 800 people
- Sponsor
- University of Zurich
HIV-1-infection on Healthy Volunteers
The Effect of Dolutegravir on Whole-body Insulin Sensitivity, Lipid and Endocrine Profile in Healthy Volunteers
This study will investigate changes in insulin resistance, lipid metabolism and endocrine profile in HIV-negative subjects exposed to dolutegravir (an antiretroviral drug used in HIV treatment) in order to investigate the role…
- Trial name
- DTG Clamp (NCT04771754)
- Testing
- Dolutegravir
- Where
- United Kingdom
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Chelsea and Westminster NHS Foundation Trust
HIV Infections
Safety of Recombinant HIV Vaccines in HIV Infected Young Adults on Stable Therapy
The purpose of this study is to determine the safety of two recombinant HIV vaccines in HIV infected young adults on stable anti-HIV therapy.
- Trial name
- NCT00107549
- Testing
- rMVA-HIV (env/gag [TBC-M358] + tat/rev/nef-RT [TBC-M335)]), rFPV-HIV (env/gag [TBC-F357] + tat/rev/nef-RT [TBC-F349])
- Where
- 9 sites in United States, Puerto Rico
- Volunteers
- 20 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV-1-infection, Subtype b
Evaluation of the Safety and the Tolerability of a Combination of Two HIV Inducers in Patients With Undetectable Viral Load
The ANRS 171 SYNACTHIV trial is a monocenter pilot open label phase I trial. This trial will evaluate new procedures in LRA administration in 3 successive cohorts.
- Trial name
- SYNACTHIV (NCT05230368)
- Testing
- Decitabine cycle 1, Romidepsin cycle 1, Decitabine cycle 2
- Where
- 4 sites in Belgium, France
- Volunteers
- 9 people
- Sponsor
- ANRS, Emerging Infectious Diseases
HIV Infections
Combination of Efavirenz and Truvada - COMET Study
To characterize the risks (safety and tolerability), effectiveness (continued viral load suppression and CD4 changes), and benefits (safety, tolerability, adherence, general satisfaction with the treatment regimen and QoL), of…
- Trial name
- NCT00224458
- Testing
- Truvada, efavirenz
- Volunteers
- 400 people
- Sponsor
- Gilead Sciences
HIV Infections
A Phase II Study of Low-Dose Interleukin-2 by Subcutaneous Injection in Combination With Antiretroviral Therapy Versus Antiretroviral Therapy Alone in Patients With HIV-1 Infection and at Least 3 Months Stable Antiretroviral Therapy
PRIMARY: To examine the effect of aldesleukin ( IL-2 ) on viral activity in the blood. To determine the safety of low-dose IL-2 in combination with antiretroviral therapy versus antiretroviral therapy alone.
- Trial name
- NCT00000820
- Testing
- Aldesleukin
- Where
- 10 sites in United States
- Volunteers
- 104 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV
Study to Evaluate the Safety and Effect of HIVconsv Vaccines in Combination With Histone Deacetylase Inhibitor Romidepsin on the Viral Rebound Kinetic After Treatment Interruption in Early Treated HIV-1 Infected Individuals
The BCN02-Romi study aims to evaluate a combined "kick and kill" strategy using the most immunogenic candidate vaccine available so far (HIVconsv) with the strongest latency reversal agent available at present time (romidepsin)…
- Trial name
- NCT02616874
- Testing
- MVA.HIVconsv vaccine, Romidepsin
- Where
- 2 sites in Spain
- Volunteers
- 15 people
- Sponsor
- IrsiCaixa
Healthy
A Study of Heterologous Vaccine Regimen of Adenovirus Serotype 26 Mosaic4 Human Immunodeficiency Virus(Ad26.Mos4.HIV), Adjuvanted Clade C gp140 and Mosaic gp140 to Prevent HIV-1 Infection Among Cis-gender Men and Transgender Individuals Who Have Sex With Cis-gender Men and/or Transgender Individuals
The purpose of this study is to evaluate the vaccine efficacy (VE) of a heterologous vaccine regimen utilizing Ad26.Mos4.HIV and aluminum phosphate-adjuvanted Clade C gp140 and Mosaic gp140 for the prevention of HIV-1 infection…
- Trial name
- MOSAICO (NCT03964415)
- Testing
- Ad26.Mos4.HIV, Clade C and Mosaic gp140 HIV bivalent vaccine
- Where
- 53 sites in United States, Argentina and 7 more
- Volunteers
- 3,900 people, healthy volunteers welcome
- Sponsor
- Janssen Vaccines & Prevention B.V.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.